Trung Huynh
Stock Analyst at RBC Capital
(4.71)
# 156
Out of 5,150 analysts
62
Total ratings
67.44%
Success rate
24.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Initiates: Underperform | $25 | $26.62 | -6.09% | 7 | Feb 25, 2026 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,250 | $1,003.57 | +24.56% | 11 | Feb 25, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Sector Perform | $60 | $62.33 | -3.74% | 6 | Feb 25, 2026 | |
| ABBV AbbVie | Initiates: Outperform | $260 | $236.19 | +10.08% | 2 | Feb 25, 2026 | |
| MRK Merck & Co. | Initiates: Outperform | $142 | $120.28 | +18.06% | 5 | Feb 25, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $787.50 | -16.19% | 5 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $149.88 | +48.79% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.42 | +1,660.56% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $379.27 | -16.42% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $29.54 | +28.64% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $7 | $3.43 | +104.08% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $8.87 | +46.56% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $245.30 | -28.66% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.66 | - | 1 | Mar 23, 2021 |
Pfizer
Feb 25, 2026
Initiates: Underperform
Price Target: $25
Current: $26.62
Upside: -6.09%
Eli Lilly and Company
Feb 25, 2026
Initiates: Outperform
Price Target: $1,250
Current: $1,003.57
Upside: +24.56%
Bristol-Myers Squibb Company
Feb 25, 2026
Initiates: Sector Perform
Price Target: $60
Current: $62.33
Upside: -3.74%
AbbVie
Feb 25, 2026
Initiates: Outperform
Price Target: $260
Current: $236.19
Upside: +10.08%
Merck & Co.
Feb 25, 2026
Initiates: Outperform
Price Target: $142
Current: $120.28
Upside: +18.06%
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $787.50
Upside: -16.19%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $149.88
Upside: +48.79%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.42
Upside: +1,660.56%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $379.27
Upside: -16.42%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $29.54
Upside: +28.64%
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $3.43
Upside: +104.08%
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $8.87
Upside: +46.56%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $245.30
Upside: -28.66%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.66
Upside: -